FilingReader Intelligence

Hengrui Medicine receives approval for pain medication expansion

March 17, 2025 at 07:01 AM UTCBy FilingReader AI

Jiangsu Hengrui Medicine (SSE:600276) announced it has received a drug registration certificate from the National Medical Products Administration (NMPA) for Fumarate Taiseglidine Injection, a Class 1 innovative drug. The approval expands the drug's indication to include the treatment of moderate to severe postoperative pain following orthopedic surgery. This indication will be combined with the previously approved indication for abdominal surgery. Postoperative pain affects a significant portion of surgical patients in China. Fumarate Taiseglidine Injection is a µ-opioid receptor (MOR) agonist. Hengrui has invested approximately 197.91 million RMB in the research and development of this project to date. The company cautions that the production and sales of the drug are subject to uncertainties and advises investors to exercise caution.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SSE:600276Shanghai Stock Exchange
Shanghai Blue Chip

News Alerts

Get instant email alerts when Jiangsu Hengrui Medicine publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →